FDA Approves Pentacel, a Paediatric Combination Vaccine
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Pentacel, a Paediatric Combination Vaccine

NEW YORK -- June 23, 2008 -- The US Food and Drug Administration (FDA) has approved Pentacel vaccine for active immunisation against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b.

Pentacel is approved for use in infants and children aged 6 weeks to 4 years (prior to fifth birthday) and is administered as a 4-dose series at 2, 4, 6, and 15 to 18 months of age. The first dose may be given as early as 6 weeks of age.

"The FDA approval of Pentacel vaccine is great news for parents and paediatricians who want to reduce the stress of well-baby visits," said Tina Q. Tan, MD, Children's Memorial Hospital, Chicago, Illinois.

"Pertussis disease continues to remain a threat to young infants, who are at the highest risk for severe complications and death. With a 4-dose primary series of Pentacel vaccine, paediatricians can reduce the number of vaccination shots while providing protection against 5 diseases, including pertussis."

The FDA approval is based on the results of multicentre clinical studies conducted in the United States and Canada involving more than 5,000 children who received at least 1 dose of the vaccine.

The immunogenicity and safety of Pentacel were compared to separately administered, single-entity, vaccine formulations. Local and systemic reactions following administration of Pentacel were reported at rates consistent with those of the separately administered vaccines used in each trial.

SOURCE: Sanofi Pasteur

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities